Fulcrum Therapeutics Reported In-line with Estimates

Fulcrum Therapeutics (FULC) reported a loss of $0.21 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.21 per share. The company reported in-line with consensus estimates.

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and Phase 3 for the treatment of COVID-19. Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia into Phase 1 clinical development.